<b><i>In vivo</i> imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand</b>

Herder, Wouter W. de; Reijs, Ambroos E.M.; Kwekkeboom, Dik J.; Hofland, Leo J.; Nobels, Frank; Oei, H. Y.; Krenning, Eric P.; Lamberts, Steven W. J.

doi:10.1046/j.1365-2265.1996.8650876.x

Cited by 35 publications

(18 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DA -D2R is thus known to regulate multiple transduction pathways. Conversely, imaging in a patient with TSHoma using radiolabeled D2R radioligand reportedly yielded negative results (25). This may suggest a deterioration in affinity due to structural abnormalities in D2R.…”

Section: Discussionmentioning

confidence: 95%

Thyrotropin-producing pituitary adenoma associated with Graves' disease

Koriyama

Nakazaki

Hashiguchi

et al. 2004

European Journal of Endocrinology

View full text Add to dashboard Cite

Objectives: The examination of potential associations between Graves' disease and thyrotropin-producing pituitary adenoma (TSHoma) after treatment using octreotide, and of the expression of peroxisome proliferator-activated receptor g (PPARg). Design and methods: A specimen of resected TSHoma tissue from our case was immunohistochemically examined for expression of somatostatin receptor 2A (SSTR2A) and PPARg. Specimens of thyroid tissue from two cases with Hashimoto's thyroiditis were immunohistochemically examined for expression of SSTR2A.

show abstract

Section: Discussionmentioning

confidence: 95%

Thyrotropin-producing pituitary adenoma associated with Graves' disease

Koriyama

Nakazaki

Hashiguchi

et al. 2004

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Radiolabeled receptor ligands (that are known in vitro to be expressed by pituitary tumors) and receptor imaging (i.e. type 2 dopamine receptor) are not widely used to localize pituitary tumors or to predict response to treatment [98].…”

Section: Advances In the Imaging Of Pediatric Pituitary Adenomasmentioning

confidence: 99%

Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics

Keil

Stratakis

2008

Expert Review of Neurotherapeutics

123

View full text Add to dashboard Cite

Pituitary tumors are rare in childhood and adolescence, with a reported prevalence of up to 1 per million children. Only 2 -6% of surgically treated pituitary tumors occur in children. Although pituitary tumors in children are almost never malignant and hormonal secretion is rare, these tumors may result in significant morbidity. Tumors within the pituitary fossa are of two types mainly, craniopharyngiomas and adenomas; craniopharyngiomas cause symptoms by compressing normal pituitary, causing hormonal deficiencies and producing mass effects on surrounding tissues and the brain; adenomas produce a variety of hormonal conditions such as hyperprolactinemia, Cushing disease and acromegaly or gigantism. Little is known about the genetic causes of sporadic lesions, which comprise the majority of pituitary tumors, but in children, more frequently than in adults, pituitary tumors may be a manifestation of genetic conditions such as multiple endocrine neoplasia type 1 (MEN 1), Carney complex, familial isolated pituitary adenoma (FIPA), and McCune-Albright syndrome. The study of pituitary tumorigenesis in the context of these genetic syndromes has advanced our knowledge of the molecular basis of pituitary tumors and may lead to new therapeutic developments.

show abstract

“…BIM compounds were provided by Biomeasure, Inc. (Milford, MA, USA). BIM-23A387 and BIM-23A760 are chimeric molecules that combine structural elements of both somatostatin and dopamine and retain affinity for both sst 2 and D 2 , and sst 2 , sst 5 , and D 2 respectively (41).…”

Section: Observations)mentioning

confidence: 99%

Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas

Ferone

Pivonello²,

Resmini³

et al. 2007

eur j endocrinol

View full text Add to dashboard Cite

Pituitary tumors can cause symptoms of mass effect and hormonal hypersecretion that can be reversed with surgical resection or debulking of the adenoma, radiotherapy, or medical treatment. Medical treatment is the primary choice for prolactinomas because dopamine agonists are very effective in the treatment of these tumors, with rates of control (tumor size reduction and hormone suppression) as high as 80-90% for microprolactinomas and 60-75% for macroprolactinomas. The function of dopamine receptors in other histotypes of pituitary adenoma is still debated. However, new insights into receptor physiology and the introduction of new clinically available, as well as experimental, compounds have reopened a potential role of dopaminergic drugs in the medical treatment of pituitary tumors. The differences between the effectiveness and the resistance to different dopaminergic agents, the new challenging results from clinical and experimental studies, as well as the future of dopamine agonists in the therapy of pituitary tumors are discussed. European Journal of Endocrinology 156 S37-S43

show abstract

In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand

Cited by 35 publications

References 20 publications

Thyrotropin-producing pituitary adenoma associated with Graves' disease

Thyrotropin-producing pituitary adenoma associated with Graves' disease

Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics

Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas

Contact Info

Product

Resources

About